雄激素非依赖性前列腺癌的研究进展

g en reˉceptor coregulatory proteins in prostate cancer and stromal-cell culture models.Prostate，2000，45:124-131. 21 Hellawell GO，Ferguson DJ，Brewster SF，et al.Chemosensitization of huˉman prostate cancer using antisense agents tareting the type1in sulin-like growth factor receptor.BJU Int，2003，91（3）:271-277. 22 Weeraratna AT，Arnold JT，George D，et al.Rational basis for trk inhibiˉtion therapy for prostate cancer.Prostate，2000，45:140-148. 23 Scher HI，Sarkis A，Reuter V，et al.Changing pattern of expressi on of the epidermal growth factor receptor and transforming growth fact or in the progression of prostatic neoplasms.Clin Cancer Res，1995，1:5 45-550. 　　24 Sirotnak FM，She Y，Lee F，et al.Studies with CWR22xenografts in nude mice suggest that ZD1839may have a role in the treatment of both anˉdrogen-dependent and androgen-independent human prostate cancer.Cli n Cancer Res，2002，8（12）:3870-3876. 25 Colombel M，Symmans F，Gil S，et al.Detection of the apoptosis-s upˉpressing oncoprotein bcl-2in hormone-refractory human prostate canˉ cer.Am J Pathol，1993，143（2）:390-400. 26 Raffo AJ，Perlman H，Chen MW，et al.Overexpression of bcl-2resis ˉtance to androgen depletion in vivo.Cancer Res，1995，55（19）:4438-4 445. 27 Kelly WK，Scher HI.Prostate specific antigen decline after antia ndrogen withdrawal:The flutamide withdrawal syndrome.J Urol，1993，149（ 3）:607-609. 28 Oefelein MG，Ricchiuti VS，Conrad PW，et al.Clinical predictors of anˉdrogen-independent prosate cancer and survival in the prostate-s peˉcific antigen era.Urology，2002，60（1）:120-124. 29 Scher HI，Kelly WK.Flutamide withdrawal syndrome:Its impact on c liniˉcal trials in hormone-refractory prostate cancer.J Clin Oncol，19 93，11（8）:1566-1572. 30 OH WK.Secondary hormonal therapies in the treatment of prostate canˉ cer.Urology，2002，60（3Suppl1）:87-92;discussion93. 　　31 Peehl DM，Seto E，Feldman D，et al.Rationale for combination ket oconaˉzole/vitamin D treatment of prostate cancer.Urology，2001，58（2 Suppl1）:123-126. 32 Saika T，Kusaka N，Tsushima T，et al.Treatment of androgen-indep enˉdent prostate cancer with dexamethasone:a prostpective study in sta ge D2patients.Int J Urol，2001，8（6）:290-294. 33 OH WK，Kantoff PW.Management of hormone refractory prostate canˉ cer.Current standards and future prospects.J Urol，1998，160（4）:1220- 1229. 34 Millikan R，Thall PF，Lee SJ，et al.Randomized，multicenter，pha seⅡtrial of two multicomponent regimens in androgen-independent prosta te cancer.J Clin Oncol，2003，21（5）:878-883. 35 Beer TM，Bubalo JS.Effects of docetaxel on pain due to metastati c anˉdrogen-independent prostate cancer.Curr Urol Rep，2002，3（3）:23 2-238. 36 Fox WD，Higgins B，Maiese KM，et al.Antibody to vascular endothe lial growth factor slows growth of an androgen-independent xenograft mo del of prostate cancer.Clin Cancer Res，2002，8（10）:3226-3231. 37 Seidman AD，Scher HI，Petrylak D，et al.Estramustine and vinblas tine:Use of prostate specific antigen as a clinical tr

《雄激素非依赖性前列腺癌的研究进展(第4页)》